| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 06/23/2011 | US20110150834 Crth2 modulators |
| 06/23/2011 | US20110150833 Benzopyrans and analogs as rho kinase inhibitors |
| 06/23/2011 | US20110150832 Furin-knockdown bi-functional rna |
| 06/23/2011 | US20110150831 Novel naphthyridine derivatives and the use thereof as kinase inhibitors |
| 06/23/2011 | US20110150830 Covalent conjugates between endoperoxides and transferrin and lactoferrin receptor-binding agents |
| 06/23/2011 | US20110150829 Antiviral nucleosides |
| 06/23/2011 | US20110150828 Interleukin-2/soluble tgf-beta type ii receptor b conjugates and methods and uses thereof |
| 06/23/2011 | US20110150827 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors |
| 06/23/2011 | US20110150826 Agent for the treatment and/or prophylaxis of an autoimmune disease and for the formation of regulatory t cells |
| 06/23/2011 | US20110150825 Uses of selective inhibitors of hdac8 for treatment of inflammatory conditions |
| 06/23/2011 | US20110150824 Nutritional Composition for Improving the Mammalian Immune System |
| 06/23/2011 | US20110150823 Cell Tissue Gel Containing Collagen and Hyaluronan |
| 06/23/2011 | US20110150785 Light Inhibitors For Asthma, Lung and Airway Inflammation, Respiratory, Interstitial, Pulmonary and Fibrotic Disease Treatment |
| 06/23/2011 | US20110150781 Tissue kallikrein for the treatment of parkinson's disease |
| 06/23/2011 | US20110150780 Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics |
| 06/23/2011 | US20110150778 Assembly of Gas-Filled Microvesicle With Active Component For Contrast Imaging |
| 06/23/2011 | US20110150769 Identification and use of compounds for treating persistent pain |
| 06/23/2011 | US20110150768 Compositions and methods for delivering inhibitory oligonucleotides |
| 06/23/2011 | US20110150764 Stroke-tageting peptide and use thereof |
| 06/23/2011 | US20110150763 Triazine derivatives and their therapeutical applications |
| 06/23/2011 | US20110150757 Compounds for inhibiting ksp kinesin activity |
| 06/23/2011 | CA2784784A1 Fusion polypeptide against eb virus-induced tumor and colicin ia mutant |
| 06/23/2011 | CA2784646A1 Hcv combination therapy |
| 06/23/2011 | CA2784624A1 Crystal of recombinant interferon with altered spatial configuration, three-dimensional structure and uses thereof |
| 06/23/2011 | CA2784145A1 Methods and compositions related to clot-binding compounds |
| 06/23/2011 | CA2784091A1 Use of a neurofilament peptide for the treatment of glioma |
| 06/23/2011 | CA2783969A1 A novel vaccine that targets tumor vessels as an efficient tool in tumor therapy |
| 06/23/2011 | CA2783296A1 Growth hormone composition |
| 06/23/2011 | CA2782236A1 Treatment composition and method |
| 06/23/2011 | CA2782131A1 Peptide |
| 06/22/2011 | EP2336368A1 Endogenous retroviruses up-regulated in prostate cancer |
| 06/22/2011 | EP2336331A1 Novel proteases and variants thereof |
| 06/22/2011 | EP2336322A1 Inhibitors of vascular endothelial growth factor activity, their uses and processes for their production |
| 06/22/2011 | EP2336321A1 Ox2 receptor homolog |
| 06/22/2011 | EP2336319A1 Antisense modulation of apolipoprotein B expression |
| 06/22/2011 | EP2336318A1 Antisense modulation of apolipoprotein B expression |
| 06/22/2011 | EP2336192A1 Conjugates of hydroxyalkyl starch and a protein, prepared by reductive amination |
| 06/22/2011 | EP2336190A2 Anti-VEGF antibodies |
| 06/22/2011 | EP2336184A2 Administration of agents for the treatment of inflammation |
| 06/22/2011 | EP2336178A1 Methods and compositions for inhibiting C-Met dimerization and activation |
| 06/22/2011 | EP2336169A1 G protein coupled receptor (GPCR) agonists and antagonists and methods of activating and inhibiting GPCR using the same |
| 06/22/2011 | EP2336168A1 Novel protein and method for producing the protein |
| 06/22/2011 | EP2336167A1 MHC molecule constructs and their uses for diagnosis and therapy |
| 06/22/2011 | EP2336166A1 Compositions that inhibit proliferation of cancer cells |
| 06/22/2011 | EP2336165A1 Peptides and compounds that bind to the thrombopoietin receptor |
| 06/22/2011 | EP2336163A1 Sclerostin binding agents |
| 06/22/2011 | EP2336162A1 Novel poly (ethylene glycol) modified erythropoietin agonists and uses thereof |
| 06/22/2011 | EP2336161A2 Amyloid-beta(1-42) oligomers, derivatives thereof, antibodies for the same, method for production and use thereof. |
| 06/22/2011 | EP2336160A2 Amyloid-beta(1-42) oligomers, derivatives thereof, antibodies for the same, method for production and use thereof. |
| 06/22/2011 | EP2336159A2 Amyloid-beta(1-42) oligomers, derivatives thereof, antibodies for the same, method for production and use thereof. |
| 06/22/2011 | EP2336151A1 Replikin peptides and uses thereof |
| 06/22/2011 | EP2336150A2 Replikin peptides and uses thereof |
| 06/22/2011 | EP2336145A1 Antisense modulation of apolipoprotein B expression |
| 06/22/2011 | EP2335738A1 Stem-cell, precursor cell or target cell-based treatment of wound healing |
| 06/22/2011 | EP2335736A1 Pharmaceutical composition utilising combinations of variants of the gonadotropin-liberating hormone (gnrh) as immunogen |
| 06/22/2011 | EP2335733A1 Specific therapy using integrin ligands for treating cancer |
| 06/22/2011 | EP2335732A2 Multiple-variable dose regimen for treating TNF-alpha-related disorders |
| 06/22/2011 | EP2335731A2 Multiple-variable dose regimen for treating TNF-alpha-related disorders |
| 06/22/2011 | EP2335726A1 Fusion molecules and methods for treatment of immune diseases |
| 06/22/2011 | EP2335724A1 Immunisation against chlamydia trachomatis |
| 06/22/2011 | EP2335723A1 Immunisation against chlamydia trachomatis |
| 06/22/2011 | EP2335722A2 Use of gelsolin to treat infections |
| 06/22/2011 | EP2335719A1 Use of hemojuvelin fusion proteins to regulate hepcidin-mediated iron metabolism |
| 06/22/2011 | EP2335718A1 Non-cytotoxic protein conjugates |
| 06/22/2011 | EP2335717A1 PAR-1 antagonists for use in the treatment or prevention of influenza virus type a infections |
| 06/22/2011 | EP2335716A2 Pancreatic polypeptide family motifs and polypeptides comprising the same |
| 06/22/2011 | EP2335715A2 Pancreatic polypeptide family motifs and polypeptides comprising the same |
| 06/22/2011 | EP2335714A1 A complex comprising IL-6 and soluble IL-6 receptor for use in the treatment of renal failure |
| 06/22/2011 | EP2335713A2 Neublastin variants |
| 06/22/2011 | EP2335700A1 Hepatitis C virus polymerase inhibitors with a heterobicylic structure |
| 06/22/2011 | EP2335694A1 Thyroid hormone analogs and methods of use. |
| 06/22/2011 | EP2335693A2 Therapeutic use of nitric oxide precursor |
| 06/22/2011 | EP2335689A1 Method of manufacturing nucleic acid micropheres |
| 06/22/2011 | EP2335070A1 Compositions and methods for detection of antibodies specific for anaplasma phagocytophilum (aph) and anaplasma platys (apl) |
| 06/22/2011 | EP2334826A2 Method of detection and diagnosis of oral and nasopharyngeal cancers |
| 06/22/2011 | EP2334697A1 Peptidomimetic macrocycles |
| 06/22/2011 | EP2334695A1 Therapeutic ribonucleases |
| 06/22/2011 | EP2334326A2 Mimotopes of alpha-synuclein and vaccines thereof for the treatment of neurodegenerative disorders |
| 06/22/2011 | EP2334324A2 Bbeta (15-42) and its analogues combined with cyclosporine for treatment of reperfusion injury |
| 06/22/2011 | EP2334323A2 Compositions and methods for the prevention of oxidative degradation of proteins |
| 06/22/2011 | EP2334322A2 Glp-1 fusion polypeptides |
| 06/22/2011 | EP2334321A2 Analysis of hcv genotypes |
| 06/22/2011 | EP2334320A2 Biopolymer conjugates comprising an interleukin-11 analog |
| 06/22/2011 | EP2334319A1 Method for reducing scarring during wound healing using antisense compounds directed to ctgf |
| 06/22/2011 | EP2334318A2 Hiv-1 integrase derived stimulatory peptides interfering with integrase - rev protein binding |
| 06/22/2011 | EP2334317A2 Stapled peptides and method of synthesis |
| 06/22/2011 | EP2334315A2 Agents and methods for treatment of pain |
| 06/22/2011 | EP2334314A1 Process for the preparation of pramlintide |
| 06/22/2011 | EP2334308A1 Treating or preventing gout |
| 06/22/2011 | EP2334306A2 Methods of modulating gastrointestinal tract flora levels with alkaline phosphatase |
| 06/22/2011 | EP2334303A1 Tyrosine kinase receptor tyro3 as a therapeutic target in the treatment of cancer |
| 06/22/2011 | EP2334300A2 Composition and method for treatment of preterm labor |
| 06/22/2011 | EP2095825B1 Method for treating human diseases associated with an increased deoxyribonucleic acid content in extracellular spaces of tissues and a medicinal preparation for carrying out said method |
| 06/22/2011 | EP1987062B1 Peptides and peptide derivatives as well as pharmaceutical compositions containing the same |
| 06/22/2011 | EP1888624B1 Method of purifying apo-2 ligand/trail using crystallisation in the cold |
| 06/22/2011 | EP1797111B1 Acylsulfonamide compounds as inhibitors of hepatitis c virus ns3 serine protease |
| 06/22/2011 | EP1773395B1 A method for managing cholesterol with a serum-free and mitogen free cytokine mixture |
| 06/22/2011 | EP1724342B1 Process for preparing variant of erysipelothrix rhusiopathiae surface protective antigen in e. coli |
| 06/22/2011 | EP1680507B1 Bacterial expression of protease inhibitors and variants thereof |
| 06/22/2011 | EP1660115B1 Pharmaceutical combination of g-csf and plgf useful for blood stem cell |